RxDoctor Payments DataLook up a doctor →

Sara White, NP

Acute Care · Santa Fe, NMNPI 1336801406

Payments from drug & device makers

$11,223in general payments, 2019–2025

Across 530 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$950
  • Johnson & Johnson$759
  • Incyte Corporation$591
  • Bristol Myers Squibb$554
  • Exelixis Inc.$430
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,65386%
  • Education$7727%
  • Other$7987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis72$1,925
AstraZeneca(2 entities)50$950
Johnson & Johnson33$759
Incyte Corporation28$591
Bristol Myers Squibb46$554
Exelixis Inc.17$430
Takeda Pharmaceuticals U.S.A., Inc.13$386
Merck16$351
Sanofi16$343
Seagen Inc.6$266
Sobi, Inc6$265
E.r. Squibb & Sons, L.L.C.15$261
Genentech USA, Inc.16$257
AbbVie10$232
Eisai Inc.12$218
Lilly USA, LLC12$184
Karyopharm Therapeutics Inc.9$175
Jazz Pharmaceuticals Inc.8$172
Amgen11$170
Bayer9$170
Tersera Therapeutics LLC6$148
AVEO Pharmaceuticals, Inc.4$145
Astellas Pharma US Inc8$143
Array Biopharma Inc8$135
Mirati Therapeutics, Inc.5$118
Daiichi Sankyo Inc.5$118
Genmab U.S., Inc.5$115
Stemline Therapeutics Inc.5$106
Puma Biotechnology, Inc.5$106
EMD Serono, Inc.5$101
Beigene USA, Inc.5$100
Regeneron Healthcare Solutions, Inc.3$90
Servier Pharmaceuticals LLC4$87
Pharmacyclics LLC, An Abbvie Company4$78
Pharmaessentia USA Corporation4$75
Blueprint Medicines Corporation3$75
Kyowa Kirin, Inc.3$65
Pfizer3$64
Beone Medicines USA, Inc.3$53
GSK3$49
Taiho Oncology, Inc.3$45
Myovant Sciences Inc.2$40
Adaptive Biotechnologies Corporation2$37
G1 Therapeutics, Inc.2$36
Boehringer Ingelheim2$36
Gilead(2 entities)2$36
CTI Biopharma Corp.2$33
Ipsen Biopharmaceuticals, Inc2$31
Springworks Therapeutics, Inc.2$31
Dendreon Pharmaceuticals LLC1$30
Geron Corporation1$29
Menarini Silicon Biosystems, Inc.1$25
Nuvation Bio Inc.1$21
Tempus AI, Inc1$21
Amneal Pharmaceuticals LLC1$18
Agios Pharmaceuticals, Inc.1$17
Tolmar Pharmaceuticals, Inc.1$17
Legend Biotech USA Inc.1$17
Rigel Pharmaceuticals, Inc.2$17
Coopersurgical, Inc.1$17

How this compares

$11,223 in reported general payments places this provider in the 95th percentile of 132 acute care providers in New Mexico.

See all acute care providers in New Mexico

Medicare billing

Part B allowed, 2024
$42,982
Medicare patients
195
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide17$222,495
Ondansetron OdtOndansetron20$738
Dexamethasone24$375
Prochlorperazine Maleate18$277
Acyclovir11$195
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$174
ValacyclovirValacyclovir Hcl11$147
Levothyroxine Sodium13$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$143$222,49517 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$6513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 132 acute care providers in New Mexico.

Other acute care in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →